Imanol Arozarena completed his PhD in Dr. Piero Crespo's laboratory at the University of Cantabria, where he studied the RAS/MAPK pathway. He subsequently, pursued postdoctoral research at the Institute of Cancer Research in London (2006-2009) and at the University of Manchester (2010-2014), where he worked on melanoma skin cancer in the laboratories of Dr. Richard Marais and Dr. Claudia Wellbrock. During this period, Dr. Arozarena focused on the mechanisms of metastatic dissemination and resistance to targeted therapies of tumor cells. After two years working as a professor and Principal Investigator at the University of Huddersfield, he established the Cancer Signaling Unit at Navarrabiomed where he continued his research on melanoma. In the last 8 years he has also developed other research lines focused on brain tumors such as glioblastoma multiforme and metastatic breast cancer. Currently, the Cancer Signaling Unit focuses on investigating the molecular mechanisms and metabolic adaptation that tumor cells develop in response to therapies commonly used in clinical practice such as radiotherapy and immunotherapy.
